Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pembrolizumab study in relapsed or refractory primary mediastinal large B-cell lymphoma or Richter syndrome
2015-002406-37Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in primary mediastinal large B-cell lymphoma (PMBCL) and Richter's syndrome (RS) (2 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)Richter's syndrome (RS)
Beyond the preview
Go deeper on 2015-002406-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002406-37.